Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Provision Holding to Present at Maxim Group Consumer Technology Conference
-
Maxim Group LLC Appoints Four Managing Directors in Equity Research Division
-
Maxim Group Upgrades Potbelly Corp (PBPB) to Buy
-
Reminder: Product Tanker Sector Webinar
-
National Energy Services Reunited Corp. Announces Closing of Partial Over-Allotment Exercise in Connection with its Initial Public Offering
-
National Energy Services Reunited Corp. Announces Closing of Partial Over-Allotment Exercise in Connection with its Initial Public Offering
-
UPDATE - Product Tanker Sector Webinar
-
Product Tanker Sector Webinar
-
UPDATE: Inovio Pharmaceuticals (INO) PT Raised to $12 at Maxim Group; 'A Step Closer to HIV Vaccine, PENNVAX-GP Demonstrates High Immune Response Rates'
-
Maxim Group Announces Strategic Promotions in Healthcare Research
-
New Age Beverages Corp (NBEV) PT Raised to $7.50 at Maxim Group
-
UPDATE: Maxim Group Upgrades Buffalo Wild Wings, Inc. (BWLD) to Buy, PT to $180; 'Potential Upside Offsets Potential Risk'
-
2017 Marcum MicroCap Conference Panels: Topics for All Segments of the Small Cap Equities Market
-
Maxim Group Upgrades BioLineRx (BLRX) to Buy
-
National Energy Services Reunited Corp. Completes $210,000,000 Initial Public Offering
-
National Energy Services Reunited Corp. Completes $210,000,000 Initial Public Offering
-
SITO Mobile Issues Open Letter to Stockholders
-
Coherus Biosciences (CHRS) PT Raised to $44 at Maxim Group; 'David Delivers a Blow to Goliath - Humira Patent '135 Falls'
-
Maxim Group Downgrades Mateon Therapeutics (MATN) to Hold
-
New Age Beverages Corporation Announces Investor Conference Call to Discuss First Quarter 2017 Results
-
National Energy Services Reunited Corp. Announces Pricing of $210,000,000 Initial Public Offering
-
National Energy Services Reunited Corp. Announces Pricing of $210,000,000 Initial Public Offering
-
Maxim Group Downgrades Syneron Medical (ELOS) to Hold
-
Red Robin Gourmet Burgers (RRGB) PT Raised to $75 at Maxim Group Ahead of 1Q Release
-
Maxim Group Starts Control4 Corporation (CTRL) at Hold
-
Gladstone Investment (GAIN) Prices 2.1M Common Stock Offering at $9.38/Share
-
Gladstone Investment Corporation Prices Common Stock Offering
-
Gladstone Investment (GAIN) Plans Common Stock Offering
-
Gladstone Investment Corporation Announces Common Stock Offering
-
Keryx Biopharma (KERX): Expanding Model And Raising PT - Maxim
-
Walker Innovation Announces First Quarter 2017 Results
-
National Beverage (FIZZ) 'Rebukes' Maxim Report
-
National Beverage Corp. Rebukes Maxim Report
-
Pre-Open Movers 05/04: (TLRD) (CNAT) (FIT) Higher; (BPMX) (SRC) (FIZ) Lower (more...)
-
Immune Pharma (IMNP) Announces Private Placement of up to $3.4M of Convertible Debentures
-
Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million
-
Maxim Group Starts New Age Beverages Corp (NBEV) at Buy
-
Maxim Group Upgrades The KEYW Holding Corporation (KEYW) to Buy
-
UPDATE: Maxim Group Starts National Beverage (FIZZ) at Sell, Overvalued Stock, Corp. Governance Riddled With Red Flags
-
Maxim Group Downgrades Potbelly Corp (PBPB) to Hold
-
Agility Health Reports 2016 Financial Results
-
Ember Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
-
ContraVir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
-
Æterna Zentaris (AEZS) PT Lowered to $2 at Maxim Group, Keeps 'Buy'; Value in Macrilen Now
-
ROTH Capital Partners Announces the Addition of Eric B. Cheng, Managing Director, Head of Healthcare Investment Banking
-
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
-
ContraVir Pharma (CTRV) Prices Shares/Warrant Offering at $1
-
ContraVir Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
-
Maxim Group Reiterates Buy Rating and $10 PT on CytoSorbents (CTSO) Following $1M Non-Dilutive Funding Awarded by DoD
-
Maxim Group Maintains Hold Rating on Gilead Sciences (GILD) Following Presentation of Positive GS-0976 Data for NASH

